STOCK TITAN

[SCHEDULE 13G/A] CryoPort, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Alger Associates, Inc. filed an amendment to Schedule 13G reporting beneficial ownership of 2,358,940 shares of CryoPort, Inc. common stock, representing 4.7% of the outstanding class. The filing states Alger Associates has sole voting and sole dispositive power over these shares and that the securities are held in the ordinary course of business, not for the purpose of changing or influencing control. The filing identifies Fred Alger Management, LLC and Alger Group Holdings as related entities that manage accounts holding the securities.

Alger Associates, Inc. ha presentato un emendamento al Modulo 13G segnalando la titolarità benefica di 2.358.940 azioni ordinarie di CryoPort, Inc., pari a il 4,7% della classe in circolazione. Nell'atto si dichiara che Alger Associates detiene la piena facoltà di voto e il pieno potere dispositiv o su queste azioni e che i titoli sono detenuti nell'ordinaria attività commerciale, non con l'intento di modificare o influenzare il controllo. Il documento indica inoltre Fred Alger Management, LLC e Alger Group Holdings come entità collegate che gestiscono conti che detengono tali titoli.

Alger Associates, Inc. presentó una enmienda al Anexo 13G informando la propiedad beneficiaria de 2.358.940 acciones ordinarias de CryoPort, Inc., que representan el 4,7% de la clase en circulación. La presentación indica que Alger Associates tiene el poder exclusivo de voto y disposición sobre estas acciones y que los valores se mantienen en el curso normal del negocio, sin el propósito de cambiar o influir en el control. También identifica a Fred Alger Management, LLC y Alger Group Holdings como entidades relacionadas que administran cuentas que poseen dichos valores.

Alger Associates, Inc.는 CryoPort, Inc. 보통주 2,358,940주에 대한 실질적 소유를 보고하는 Schedule 13G 수정서를 제출했으며, 이는 발행 주식의 4.7%에 해당합니다. 제출서에는 Alger Associates가 해당 주식에 대해 단독 의결권 및 단독 처분권을 보유하고 있으며, 증권은 지배권 변경이나 영향 행사 목적이 아닌 통상적인 영업 과정에서 보유되고 있다고 명시되어 있습니다. 또한 해당 증권을 보유한 계좌를 관리하는 관련 기관으로 Fred Alger Management, LLC 및 Alger Group Holdings를 밝히고 있습니다.

Alger Associates, Inc. a déposé un amendement au formulaire Schedule 13G déclarant la propriété bénéficiaire de 2 358 940 actions ordinaires de CryoPort, Inc., représentant 4,7 % de la catégorie en circulation. Le dépôt indique qu'Alger Associates exerce le pouvoir exclusif de vote et de disposition sur ces actions et que ces titres sont détenus dans le cours normal de l'activité, sans intention de modifier ou d'influencer le contrôle. Le document identifie également Fred Alger Management, LLC et Alger Group Holdings comme entités liées qui gèrent les comptes détenant ces titres.

Alger Associates, Inc. reichte eine Änderung zu Schedule 13G ein und meldete den wirtschaftlichen Besitz von 2.358.940 Stammaktien der CryoPort, Inc., was 4,7 % der ausstehenden Aktienklasse entspricht. Die Einreichung besagt, dass Alger Associates die alleinige Stimm- und Verfügungsgewalt über diese Aktien hat und dass die Wertpapiere im normalen Geschäftsverlauf gehalten werden, nicht mit dem Ziel, die Kontrolle zu verändern oder zu beeinflussen. Ferner werden Fred Alger Management, LLC und Alger Group Holdings als verbundene Stellen genannt, die Konten verwalten, die diese Wertpapiere halten.

Positive
  • Transparent disclosure of beneficial ownership and related-affiliate structure
  • Sole voting and dispositive power over 2,358,940 shares provides clear voting accountability
Negative
  • Stake is below 5%, limiting likelihood of material influence on corporate control

Insights

TL;DR: Disclosure shows a 4.7% stake with full voting and dispositive authority, indicating a meaningful passive position below the 5% reporting concern.

Alger Associates reports ownership of 2,358,940 shares and affirms ordinary-course holdings rather than an activist intent. The sole voting and dispositive power means the firm can make voting decisions, but at 4.7% the stake remains below the 5% mark that often triggers additional investor scrutiny or strategic expectations. This appears to be a portfolio position managed via affiliated investment vehicles.

TL;DR: The filing documents control over votes for a sub-5% position, so governance impact is limited but vote aggregation could matter in close matters.

While Alger Associates asserts sole voting power over 2,358,940 shares, the sub-5% ownership level constrains material influence on corporate control. The certification that holdings are not intended to change control reduces concerns about an imminent proxy campaign. Related-entity disclosures clarify fund and adviser structure, improving transparency for governance assessments.

Alger Associates, Inc. ha presentato un emendamento al Modulo 13G segnalando la titolarità benefica di 2.358.940 azioni ordinarie di CryoPort, Inc., pari a il 4,7% della classe in circolazione. Nell'atto si dichiara che Alger Associates detiene la piena facoltà di voto e il pieno potere dispositiv o su queste azioni e che i titoli sono detenuti nell'ordinaria attività commerciale, non con l'intento di modificare o influenzare il controllo. Il documento indica inoltre Fred Alger Management, LLC e Alger Group Holdings come entità collegate che gestiscono conti che detengono tali titoli.

Alger Associates, Inc. presentó una enmienda al Anexo 13G informando la propiedad beneficiaria de 2.358.940 acciones ordinarias de CryoPort, Inc., que representan el 4,7% de la clase en circulación. La presentación indica que Alger Associates tiene el poder exclusivo de voto y disposición sobre estas acciones y que los valores se mantienen en el curso normal del negocio, sin el propósito de cambiar o influir en el control. También identifica a Fred Alger Management, LLC y Alger Group Holdings como entidades relacionadas que administran cuentas que poseen dichos valores.

Alger Associates, Inc.는 CryoPort, Inc. 보통주 2,358,940주에 대한 실질적 소유를 보고하는 Schedule 13G 수정서를 제출했으며, 이는 발행 주식의 4.7%에 해당합니다. 제출서에는 Alger Associates가 해당 주식에 대해 단독 의결권 및 단독 처분권을 보유하고 있으며, 증권은 지배권 변경이나 영향 행사 목적이 아닌 통상적인 영업 과정에서 보유되고 있다고 명시되어 있습니다. 또한 해당 증권을 보유한 계좌를 관리하는 관련 기관으로 Fred Alger Management, LLC 및 Alger Group Holdings를 밝히고 있습니다.

Alger Associates, Inc. a déposé un amendement au formulaire Schedule 13G déclarant la propriété bénéficiaire de 2 358 940 actions ordinaires de CryoPort, Inc., représentant 4,7 % de la catégorie en circulation. Le dépôt indique qu'Alger Associates exerce le pouvoir exclusif de vote et de disposition sur ces actions et que ces titres sont détenus dans le cours normal de l'activité, sans intention de modifier ou d'influencer le contrôle. Le document identifie également Fred Alger Management, LLC et Alger Group Holdings comme entités liées qui gèrent les comptes détenant ces titres.

Alger Associates, Inc. reichte eine Änderung zu Schedule 13G ein und meldete den wirtschaftlichen Besitz von 2.358.940 Stammaktien der CryoPort, Inc., was 4,7 % der ausstehenden Aktienklasse entspricht. Die Einreichung besagt, dass Alger Associates die alleinige Stimm- und Verfügungsgewalt über diese Aktien hat und dass die Wertpapiere im normalen Geschäftsverlauf gehalten werden, nicht mit dem Ziel, die Kontrolle zu verändern oder zu beeinflussen. Ferner werden Fred Alger Management, LLC und Alger Group Holdings als verbundene Stellen genannt, die Konten verwalten, die diese Wertpapiere halten.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G




Comment for Type of Reporting Person: The securities reported herein are beneficially owned by one or more open-end investment companies or other managed accounts that are investment management clients of Fred Alger Management, LLC ("FAM"), a registered investment adviser. FAM is a 100% owned subsidiary of Alger Group Holdings, LLC ("AGH"), a holding company. AGH is a 100% owned subsidiary of Alger Associates, Inc., a holding company.


SCHEDULE 13G



Alger Associates, Inc.
Signature:/s/ Hal Liebes
Name/Title:Hal Liebes / Secretary
Date:08/14/2025

FAQ

How many CryoPort (CYRX) shares does Alger Associates report owning?

Alger Associates reports beneficial ownership of 2,358,940 shares.

What percentage of CYRX does this ownership represent?

The filing states the position represents 4.7% of the class.

Does Alger Associates have voting control over these shares?

Yes, the filer reports sole voting power and sole dispositive power over the 2,358,940 shares.

Is this filing indicating an attempt to take control of CryoPort?

No; the certification states the securities are held in the ordinary course of business and not acquired to change or influence control.

Who are the related entities mentioned in the filing?

The filing references investment management clients of Fred Alger Management, LLC and holding companies Alger Group Holdings and Alger Associates, Inc.
Cryoport Inc

NASDAQ:CYRX

CYRX Rankings

CYRX Latest News

CYRX Latest SEC Filings

CYRX Stock Data

454.61M
47.57M
3.67%
98.79%
5.38%
Integrated Freight & Logistics
Pharmaceutical Preparations
Link
United States
BRENTWOOD